National Institute of Infectious Diseases Operates 'Antiviral Drug Evaluation Hub Laboratory'
Evaluation of Antiviral Substance Efficacy and Support for Therapeutic Development for COVID-19 and Other Viral Diseases
[Asia Economy Reporter Jihee Kim] The National Institute of Infectious Diseases at the National Institute of Health announced on the 11th that it will begin operating the "Antiviral Drug Evaluation Hub Laboratory." The purpose is to support the efficacy evaluation of therapeutic substances for viral diseases such as COVID-19 and the development of treatments.
The Korea Disease Control and Prevention Agency selected a total of three new hub laboratories to provide continuous support and enhance expertise in response to the increasing demand from the private sector for antiviral drug efficacy evaluation using specialized facilities. These include two cell efficacy analysis laboratories (Korea University, Korea Pasteur Institute) and one animal efficacy analysis laboratory (Chungbuk National University).
The hub laboratories will perform antiviral substance efficacy evaluation analysis requested by the private sector, proficiency testing for establishing standard test methods, and collaborative research for antiviral drug discovery for one year. The cell efficacy analysis laboratories will conduct antiviral efficacy evaluations at the cellular level using rapid high-throughput screening systems and neutralization efficacy analysis methods within BSL3 facilities for various antiviral candidate substances. The animal efficacy analysis laboratory will establish animal infection models such as mice and hamsters using BSL3 facilities and an Animal Biosafety Level 3 (ABL3) wild-type virus animal infection laboratory, and will evaluate the safety and efficacy of antiviral substances.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Juyeon Lee, Director of the Emerging Virus Research Center at the National Institute of Infectious Diseases, stated, "Through the operation of the antiviral drug evaluation hub laboratories, we expect to contribute to the discovery of antiviral substances and the establishment of a non-clinical evaluation foundation not only for COVID-19 but also for future infectious diseases."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
